Cargando…

Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity

A serious adverse effect of cancer therapies is cardiovascular toxicity, which significantly limits the widespread use of antineoplastic agents. The promising new field of cardio-oncology offers the identification of potent anti-cancer therapeutics that effectively inhibit cancer cell proliferation...

Descripción completa

Detalles Bibliográficos
Autores principales: Szabó, Zoltán, Hornyák, Lilla, Miskei, Márton, Székvölgyi, Lóránt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902874/
https://www.ncbi.nlm.nih.gov/pubmed/33643029
http://dx.doi.org/10.3389/fphar.2020.569955
_version_ 1783654620197814272
author Szabó, Zoltán
Hornyák, Lilla
Miskei, Márton
Székvölgyi, Lóránt
author_facet Szabó, Zoltán
Hornyák, Lilla
Miskei, Márton
Székvölgyi, Lóránt
author_sort Szabó, Zoltán
collection PubMed
description A serious adverse effect of cancer therapies is cardiovascular toxicity, which significantly limits the widespread use of antineoplastic agents. The promising new field of cardio-oncology offers the identification of potent anti-cancer therapeutics that effectively inhibit cancer cell proliferation without causing cardiotoxicity. Future introduction of recently identified cardio-safe compounds into clinical practice (including ERK dimerization inhibitors or BAX allosteric inhibitors) is expected to help oncologists avoid unwanted cardiological complications associated with therapeutic interventions.
format Online
Article
Text
id pubmed-7902874
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79028742021-02-25 Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity Szabó, Zoltán Hornyák, Lilla Miskei, Márton Székvölgyi, Lóránt Front Pharmacol Pharmacology A serious adverse effect of cancer therapies is cardiovascular toxicity, which significantly limits the widespread use of antineoplastic agents. The promising new field of cardio-oncology offers the identification of potent anti-cancer therapeutics that effectively inhibit cancer cell proliferation without causing cardiotoxicity. Future introduction of recently identified cardio-safe compounds into clinical practice (including ERK dimerization inhibitors or BAX allosteric inhibitors) is expected to help oncologists avoid unwanted cardiological complications associated with therapeutic interventions. Frontiers Media S.A. 2021-02-10 /pmc/articles/PMC7902874/ /pubmed/33643029 http://dx.doi.org/10.3389/fphar.2020.569955 Text en Copyright © 2021 Szabó, Hornyák, Miskei and Székvölgyi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Szabó, Zoltán
Hornyák, Lilla
Miskei, Márton
Székvölgyi, Lóránt
Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
title Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
title_full Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
title_fullStr Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
title_full_unstemmed Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
title_short Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
title_sort two targets, one hit: new anticancer therapeutics to prevent tumorigenesis without cardiotoxicity
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902874/
https://www.ncbi.nlm.nih.gov/pubmed/33643029
http://dx.doi.org/10.3389/fphar.2020.569955
work_keys_str_mv AT szabozoltan twotargetsonehitnewanticancertherapeuticstopreventtumorigenesiswithoutcardiotoxicity
AT hornyaklilla twotargetsonehitnewanticancertherapeuticstopreventtumorigenesiswithoutcardiotoxicity
AT miskeimarton twotargetsonehitnewanticancertherapeuticstopreventtumorigenesiswithoutcardiotoxicity
AT szekvolgyilorant twotargetsonehitnewanticancertherapeuticstopreventtumorigenesiswithoutcardiotoxicity